[Blood-brain barrier part III: therapeutic approaches to cross the blood-brain barrier and target the brain].
Over the last few years, the blood-brain barrier has come to be considered as the main limitation for the treatment of neurological diseases caused by inflammatory, tumor or neurodegenerative disorders. In the blood-brain barrier, the close intercellular contact between cerebral endothelial cells due to tight junctions prevents the passive diffusion of hydrophilic components from the bloodstream into the brain. Several specific transport systems (via transporters expressed on cerebral endothelial cells) are implicated in the delivery of nutriments, ions and vitamins to the brain; other transporters expressed on cerebral endothelial cells extrude endogenous substances or xenobiotics, which have crossed the cerebral endothelium, out of the brain and into the bloodstream. Recently, several strategies have been proposed to target the brain, (i) by by-passing the blood-brain barrier by central drug administration, (ii) by increasing permeability of the blood-brain barrier, (iii) by modulating the expression and/or the activity of efflux transporters, (iv) by using the physiological receptor-dependent blood-brain barrier transport, and (v) by creating new viral or chemical vectors to cross the blood-brain barrier. This review focuses on the illustration of these different approaches.
Weiss
N
N
CNRS (UMR 8104), Inserm U567, université Paris-Descartes, institut Cochin, 22, rue Mechain, 75014 Paris, France.
Miller
F
F
Cazaubon
S
S
Couraud
P-O
PO
D018528:ATP-Binding Cassette Transporters / Q000037:antagonists & inhibitors; D000818:Animals; D001812:Blood-Brain Barrier / Q000378:metabolism* / Q000502:physiology; D001921:Brain / Q000187:drug effects*; D016503:Drug Delivery Systems; D006801:Humans; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000378:metabolism*
D018528:ATP-Binding Cassette Transporters; D004364:Pharmaceutical Preparations